ArticleDiscover oncology2026
Comprehensive pan-cancer analysis of FSCN1 as a marker for prognosis and immunity.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundFascin actin-bundling protein 1 (FSCN1), a member of actin cytoskeletal protein family genes, plays critical roles in cell migration, motility, adhesion, and other cellular interactions. It has shown its ascending importance in tumors of multiple systems, including the nervous system, respiratory system, digestive system and urinary system. Nevertheless, no systematic pan-cancer analysis has been carried out to investigate its function in diagnosis, prognosis, and immunological prediction.
methodsWe used UCSC Xena, The Cancer Genome Atlas (TCGA), Genotype Tissue Expression Project (GTEx), Human Protein Atlas (HPA), cBioPortal, STRING, Cancer single-cell state Atlas (CancerSEA), Genomics of Drug Sensitivity in Cancer (GDSC) and Xiantao Academic analysis tool websites and databases for the extraction of pan-cancer data on FSCN1. We adopted bioinformatics methods to explore the potential role of FSCN1 in pan-cancer, including analysis of the correlation between FSCN1 and clinicopathologic features, prognosis, genetic alteration, immune, DNA methylation, single cell function and drug sensitivity. Furthermore, a protein–protein interaction network was drawn, and gene set enrichment analysis was conducted to explore the functions of FSCN1. Finally, we validated the effects of FSCN1 on cell proliferation and apoptosis through experiments.
resultsThe findings of the comprehensive pan-cancer analysis revealed that FSCN1 was highly expressed in most cancers, except in acute myeloid leukemia, prostate adenocarcinoma and thyroid carcinoma, and it has a certain diagnostic and prognosis value in many cancers. Furthermore, FSCN1 expression was found to correlate with immune cell infiltration, immune checkpoint (ICP) genes expression, DNA methylation and drug sensitivity in a variety of cancers. In addition, we discovered that FSCN1 participated in the proliferation and DNA repair at the single-cell level. Besides, Gene function enrichment analyses revealed that genes that were co-expressed with FSCN1 were enriched within the actin filament regulation pathways. CCK-8 assay and flow cytometry apoptosis assay results indicated that FSCN1 knockdown inhibited proliferation and induced apoptosis in mesothelioma (MESO).
conclusionFSCN1 is a prospective marker for the diagnosis, prognosis, immunology, chemotherapy, and small molecular drugs targeted for pan-cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.